Biocon and Aurobindo Pharma are identified as facing significant EPS impacts within the generics and biosimilars domain.

Cipla reports a 10% YoY rise in Q1FY26 net profit, driven by strong performance in consumer healthcare and generics. The ...

As global demand for next-generation therapies on diabetes and weight loss surges, Indian pharmaceutical companies are ...

Welcome to the Cipla Stock Liveblog, your go-to platform for real-time updates and analysis on a top-performing stock. Stay ...

Indian drugmaker Aurobindo Pharma reported a lower first-quarter profit on Monday, as expenses grew faster than revenue - stung by weak prices in the key U.S. market. The company's consolidated net ...

Cipla consolidated net profit for the quarter ending June 2025 at ₹1291.61 crore was up 10% compared to ₹1175.46 crore in the ...

Cipla reported a 10% increase in consolidated profit after tax, reaching ₹1,298 crore for Q1 FY26, driven by strong sales in ...

As Cipla turns 90, the pharmaceutical giant is reimagining itself as a brand fit for a wellness-driven, digital-first India.

Ciplas Earnings Before Interest, Taxes, Depreciation and Amortisation (EBITDA) stood at Rs 1,778 crore, reflecting a 4% YoY ...

Welcome to the Cipla Stock Liveblog, your go-to platform for real-time updates and analysis on a top-performing stock. Stay ...

Cipla share price gain 3% after Q1 earnings beat estimates, with strong margins, India growth, and positive analyst sentiment ...

Nilesh Jain, Head AVP-Technical & Derivatives Research (Equity Research), Centrum Broking Ltd., has recommended three stocks ...